KI 8110

structure given in first source

Also Known As:

5-fluoro-2',3'-isopropylidene-5'-O-(4-N-acetyl-2,4-dideoxy-3,6,7,8-tetra-O-acetyl-1-methoxycarbonylglycerogalactooctapyranosyl)uridine; KI-8110; Uridine, 5'-O-(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-alpha-neuraminosyl)-5-fluoro-2',3'-O-(1-methylethylidene)-

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - KI 8110: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Uridine: 1186
        KI 8110: 5
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Uridine: 1186
      - KI 8110: 5
  - Ribonucleosides: 49
    - Uridine: 1186
      - KI 8110: 5

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 07/01/1988 - "To investigate the mechanism of this inhibition, the effect of KI-8110 on the metastatic cascade, especially on the interaction between tumor cells and platelets which may play a crucial role in tumor cell metastasis, was examined. " 03/01/1994 - "KI-8110 treatment has previously been shown to reduce sialic acid levels in each of these cell lines and to reduce hepatic metastases in CX-1 and CCL-235 cell lines. " 07/01/1988 - "These results suggest that KI-8110 inhibits experimental tumor cell metastasis by inhibiting the interaction between tumor cells and host platelets in at least two pathways, and this may be due to a reduction of sialic acid contents of the membrane surface of tumor cells." 01/29/1993 - "The sialic acid nucleoside conjugate KI-8110 has been shown to inhibit the formation of hepatic metastases from human colorectal cancer cell lines in a nude mouse intrasplenic injection model. " 04/01/1992 - "Treatment of the cell lines with KI-8110, a CMP-sialic acid derivative which prevents incorporation of sialic acid into glycoconjugates, resulted in reduced formation of hepatic metastases by the colorectal carcinoma cell lines in the nude mouse model. "
2.	Colorectal Neoplasms (Colorectal Cancer) 03/01/1990 - "We used a novel inhibitor of sialic acid incorporation, KI-8110, to determine the effect of depletion of cell surface sialic acid on the metastatic behavior of three human colorectal cancer cell lines, in which hepatic seeding was related to tumor cell differentiation. " 01/29/1993 - "The sialic acid nucleoside conjugate KI-8110 has been shown to inhibit the formation of hepatic metastases from human colorectal cancer cell lines in a nude mouse intrasplenic injection model. " 04/01/1992 - "Treatment of the cell lines with KI-8110, a CMP-sialic acid derivative which prevents incorporation of sialic acid into glycoconjugates, resulted in reduced formation of hepatic metastases by the colorectal carcinoma cell lines in the nude mouse model. "
3.	Neoplasms (Cancer) 03/01/1990 - "Treatment of tumor cells with KI-8110 prior to intrasplenic injection prevented liver colonization. " 07/01/1988 - "This activity was reduced by pretreatment of the tumor cells with KI-8110. " 07/01/1988 - "To investigate the mechanism of this inhibition, the effect of KI-8110 on the metastatic cascade, especially on the interaction between tumor cells and platelets which may play a crucial role in tumor cell metastasis, was examined. " 03/01/1990 - "We used a novel inhibitor of sialic acid incorporation, KI-8110, to determine the effect of depletion of cell surface sialic acid on the metastatic behavior of three human colorectal cancer cell lines, in which hepatic seeding was related to tumor cell differentiation. " 07/01/1988 - "These results suggest that KI-8110 inhibits experimental tumor cell metastasis by inhibiting the interaction between tumor cells and host platelets in at least two pathways, and this may be due to a reduction of sialic acid contents of the membrane surface of tumor cells."

Related Drugs and Biologics

1.	N-Acetylneuraminic Acid (Sialic Acid)
2.	Platelet-Derived Growth Factor
3.	Nucleosides
4.	Insulin (Novolin)
5.	Glycoconjugates
6.	Epidermal Growth Factor (EGF)
7.	Cytidine Monophosphate N-Acetylneuraminic Acid